The specialist in next generation antimicrobials said under the agreement, Ecolab will acquire a global license for professional markets on its technologies and buy the professional products division.
Aseptix currently sells its Aseptix-branded professional products in Europe and India to healthcare, food processing and pharmaceutical clients.
The firm is the inventor of activated hydrogen peroxide technologies, used to eradicate pathogens with material compatibility and without burdening residues. The active ingredient degrades to water and oxygen after use.
Under this transaction, Aseptix will continue to own the intellectual property of more than 60 patents around its technologies and related know-how, while Ecolab will receive exclusive rights for use of the majority of Aseptix’s technologies in markets worldwide.
Ilja Bobbert, founder and CEO of Aseptix, said it was a major milestone.
“Aseptix has laid the initial groundwork and has proven the products can lower infection rates in many industries. Now, Ecolab can truly globalize the technology across their business segments, and geographies worldwide.”